Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have to sign a CDA to participate. Please contact the investment group for further information.
That's a good question. Nobody will know until it happens. That why there are discounts available and a bottom stock price along with a ceiling price. Protects your conversion somewhat. Also you get stock options at 3/4 of a share for $3.75 a share. That might come into play with a successful drill. They do have minimum requirements to participate. When I talked to the representative he seemed flexible. I also read it was at their discretion.
The soonest you can convert seems to be after the registration date which shows 45 days after the closing date. The closing date looks to be March 24th. That should be around May 8th before can can convert.
Check it out. Look for a confirmation soon. Military contract!!! Small but it's a start...
https://www.fbo.gov/index?s=opportunity&mode=form&id=1e93f3dd713036f2245d4d2d160f1ac5&tab=core&tabmode=list&=
Check out this news report. Got this off the Yahoo Board. Watch the video. Come on military contract!!!
http://charlotte.news14.com/content/local_news/coastal/657067/marines-testing-green-tech-to-keep-soldiers-out-of-harm-s-way
Yes, that is a quote from Ray. Ray told us to hold on. Well, I'm holding...
"This actually is, I think, a very important and pertinent question because when we drill the wells, there really are three different types of results. One is obviously commercial discovery, another is a complete dry hole, but the third point, the third possibility, which is a very likely possibility, is that we find a certain amount of oil, but it may not be exactly what we thought. But the advantage there is once you have a control point, if you found some oil, proven the hydrocarbon system, if you've got a well with ties to potential reservoirs, that's a road map for going and finding where you can get higher up-dip or where you can get a thicker reservoir. And for us, finding significant amounts of oil will be a very successful outcome. So, it won't be long now until we see what we have."
The results should be announced very shortly based on this statement made by Ray. I also remember Ray saying something like if we have a dry hole, then there is no reason to log the well.
The second question is in regard to the well results. Now, we will be releasing the well results in a manner that is consistent with industry norms of offshore West Africa, and material information will be disclosed on a timely basis. Really what that means is we are going to drill the well, we are going to log it, we're going to collect samples, and then we give a summary of the important information results. We are not going to be giving daily results because as I have found from more than 30 years in this business, very often you may receive daily results and they need to be analyzed. You can jump to improper conclusions very quickly. The sensible and correct thing to do is to get the results to the well and then put out the conclusions which you believe are the correct conclusions. Once we have those conclusions, we are not going to hold them. We are going to release them immediately. But you really can look for the results as soon as the well is drilled.
http://files.shareholder.com/downloads/HDY/1559305790x6546254x498770/06eeb0b0-34c7-4011-8f6d-f1b8c39b6a6e/HDY%20Update%20Transcript%202011-09-07%20final.pdf
There was 1004 dec. $3 calls bought between $.80-.89 and 1000 $7 @ .05. Not much action on the put side. Somebody bought their lottery ticket...
Cryptography Research Announces License Agreement with Broadcom for Differential Power Analysis Countermeasures Patents
SAN FRANCISCO, CA — May 31, 2011 — Cryptography Research, Inc. (CRI) today announced that Broadcom Corporation (Nasdaq: BRCM) has signed a license agreement regarding the use of CRI’s patents. CRI focuses on combating Differential Power Analysis (DPA) and related attacks. Under the agreement, Broadcom receives the freedom to use CRI's patents.
“Broadcom is a prominent technology innovator and global leader in semiconductors for a wide range of sophisticated secure applications,” said Carole Coplan, vice president of business development, tamper resistance solutions, Cryptography Research. “We are pleased to include Broadcom among our list of leading licensed chip suppliers.”
“Protections against power analysis attacks are critical for tamper-resistant semiconductors. The DPA countermeasure license with Cryptography Research is an important ingredient in our efforts to provide our customers with strong security across our product lines,” said Dan Marotta, executive vice president & general manager, Broadcom’s Broadband Communications Group.
DPA is a form of attack that involves monitoring the fluctuating electrical power consumption of a target device and then using advanced statistical methods to derive cryptographic keys and other secrets. Strong countermeasures to DPA help protect tamper-resistant chips used in applications such as banking, pay television, mass transit, secure ID, and wireless telecommunications.
Cryptography Research has been awarded a portfolio of more than 55 patents covering countermeasures to DPA attacks, with additional patent applications pending worldwide.
Hi Ernie,
Not much conversation over at MSB on TLON. TLON is burning through over $5 million per qtr. They have around $22 of the $40 million left. The phase III trial will cause more dilution from the $60 million left on the $100 million financing deal. Will have to wait and see what the FDA wants for the NDA submission. Waited this long. What's another couple months?
I'm concerned about this from the 10-k
http://files.shareholder.com/downloa...4-11-17382.pdf
Based on the data from the rALLy study, in the first half of 2011, we plan to submit to the FDA a New Drug Application, or NDA, seeking
accelerated approval of Marqibo in Ph- adult ALL, in second or greater relapse or that has progressed following two or more prior lines of antileukemia
therapy. At a February 8, 2011 meeting of the FDA’s Oncology Drug Advisory Committee, or ODAC, the FDA indicated that a drug
sponsor and the FDA must agree on the feasibility and design of Phase 3 confirmatory studies as a necessary element in the NDA submission process for those sponsors seeking accelerated approval. According to the FDA, a sponsor seeking accelerated approval should not submit its NDA until such agreement on Phase 3 confirmatory studies has been finalized. Our NDA submission may be delayed if the FDA does not
accept our proposed confirmatory Phase 3 study.In addition, we are conducting a Phase 2 study to assess the efficacy of Marqibo in patients with metastatic malignant uveal melanoma as determined by Disease Control Rate (CR, partial response or durable stable disease). Secondary objectives are to assess the safety and antitumor activity of Marqibo as determined by response rate, progression free survival and overall survival. In addition, patients undergo continuous electrocardiographic evaluation during the first dose of Marqibo exposure. The patient population is defined as adults with uveal melanoma and confirmed metastatic disease that is untreated. We have enrolled 49 subjects to date and plan to enroll up to a total of approximately 59 subjects in this clinical trial.
So what does this mean?
They want a confirmatory phase 3 trial. From the looks of the situation, TLON is going to seek approval with phase 2 data. What the FDA wants is, prior to any accelerated approval with the limited info, a phase 3 trial design spelled out for them so that IF they approve marqibo, TLON will have to follow up with their phase 3 to maintain the approval. In this sense, patients can get marqibo as a last ditch effort for their cancer until more data comes out. If marqibo falters in the phase 3 trial it's probable that the FDA will revoke approval.
Hey Luxor,
Thanks for calling her. Sounds like Thursday instead of tomorrow. Maybe we can get to $.30 tomorrow...
Over subscribed shares showed up this morning for me on Fidelity. I over subscribe by almost double my original shares and got all of them filled. You should be good...
None if you didn’t subscribe/oversubscribe like a few people here.
A great opportunity missed by many! You were able, as I did, to buy shares between $.07 and $.09 prior to the rights offering over the last couple months. I think the share price hit $.06 once or twice in a day during that time period.
Wait for the own rights date to pass (Jan. 31st). Subscribe and oversubscribe for the offering (week later). Then judging by the drop in share price, you had up to Feb 23rd to sell those original shares for at least what you paid for them. I sold my shares for an avg. of $.09. Now all I own are the offering shares with the warrants and I made a few $$$.
Information is out there on their products. Take a look at this independent test done on the DSU filters.
The addition of the Nephros DSU to the dialysis water treatment system was able to reduce EPO usage significantly in this prospective observational trial.
At the beginning of the study, Clinic A and B were spending $17k and $24k per month on EPO for their 20 patients respectively. At the end of the study, these monthly costs had decreased to $9.5k and $14k respectively. Pre-MIPPA the clinic would suffer financially for this improvement at the ASP+6% reimbursement. However, in the bundled rate system, Clinic A would see a $28 savings ($64 vs. $36) in average EPO cost per treatment. Clinic B would see a $40 savings ($94 vs. $54) on EPO compared to the baseline. These differences would have a significant positive financial impact on the ability of dialysis clinics to manage ESA costs thereby allowing clinics to thrive.
http://www.biologicalwaterfilters.com/EPOReductiononMachinesPrevEquipwithUltrafilters.pdf
http://www.biologicalwaterfilters.com/hospital-water-filters/epo-reduction-after-installing-dsu-on-machines-equipped-with-machine-brand-ultrafilters/
Biomoda Completes Patient Enrollment and Sample Collection for Pilot
StudyBY Business Wire
— 7:00 AM ET 02/22/2011
ALBUQUERQUE, N.M.--(BUSINESS WIRE)-- Cancer diagnostics company Biomoda, Inc. (BMOD) (www.biomoda.com) today announced that it has completed patient enrollment and sample collection for the pilot study to determine the clinical sensitivity and specificity of its CyPath® diagnostic assay for the early detection of lung cancer.
“We are working closely with Dr. Thomas Bauer, Principal Investigator of the CyPath® study, and Dr. Richard Holcomb of Quintiles to evaluate and report top-line results by the end of first-quarter 2011,” Biomoda (BMOD) Chief Executive Officer Maria Zannes said. “We believe initial results will show that our assay can both identify and quantify lung cell characteristics that differ between groups of individuals at high risk for developing cancer and those who already have the disease.”
The pilot study consisted of two cohorts: (1) a high-risk group of military veterans who smoked more than 20 “pack years” and (2) a smaller positive control group made up of patients diagnosed with lung cancer who have not started treatment.
“We are grateful to the lung cancer patients who participated in our pilot study at a difficult time in their lives,” Biomoda (BMOD) President John Cousins said. “Thanks to their selflessness and the efforts of our partners at Christiana Care Health System and Waterbury Pulmonary Associates, we were able to meet our study requirements.”
Currently for investigational use only, the CyPath® labeling solution binds to cancer cells and causes them to fluoresce under specific frequencies of light. Biomoda (BMOD) is seeking Food and Drug Administration (FDA) approval of its diagnostic technology as a Class III medical device.
About Biomoda (BMOD)
Biomoda (BMOD) (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda (BMOD) management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, which are described from time to time in the Company’s filings with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.
Source: Biomoda, Inc. (BMOD
Loading...
)
Here's some good news about the water filters...
On Jan. 26, 2011, AAMI announced the adoption of a new standard for levels of bacteria and endotoxins allowed in dialysate. The standard, ANSI/AAMI/ISO 1163, replaces the AAMI RD52 standard .
http://www.biologicalwaterfilters.com/hospital-water-filters/new-ansiaamiiso-11663/
IMHO of RPC
I can’t find where RPC has FDA approval for their lung cancer test. I read somewhere they have approval for the test in Canada and I did find where they have a FDA approved product but it's for a different kind of test. Here is what they wrote, with the published results, about the FDA.
“The company expects to seek FDA registration for LC Sentinel™ in 2011. “
These test results seem too vague. The published blood test results showed that known patients with lung cancer tested positive and ones that didn’t tested negative. How is it known that this wasn’t a different kind of cancer that traveled into the lung from another part of the body or this is actually lung cancer that formed in the lung? As we all know this is very important to the FDA. This is why we have the phase 2 results delayed for BMOD.
Another issue I have with RPC is they only signed a 5 year agreement with Provista after stating this after the results.
“RPC is actively engaged in acquisition negotiations with Provista and with the success of the deal; we expect to combine both companies to achieve a leadership presence in the global cancer diagnostics market.” Wasn't the test developed by Provista? Do they or don't they own the rights to the test?
I called RPC for answers and no one has called me back!!!
http://ir.talontx.com/sec.cfm
Insider buying...
SEC Filing Alert
Talon Therapeutics has filed the following document(s) with the United States Securities and Exchange Commission.
--------------------------------------------------------------------------------
Dec 23, 2010
Form 4 / Deitcher, Steven R
HTML PDF
Form 4 / Nielsen, Tyler Marshall
HTML PDF
Form 4 / Carlson, Craig W
HTML PDF
View all SEC Filings
The Clever Bull making a good case about the potential of HANA with many catalysts coming with in the next few months.
Understanding Warburg Pincus strategy: (OTC:HNAB), (NASDAQ:ISPH), (NASDAQ:ALTH), (NASDAQ:ZGEN), (NASDAQ:EURX), (NASDAQ:ITMN), (NYSE:WX)
Written by Eric Sebastien
Oct 14, 2010
That might be a good time to look again at Hana Biosciences, as they have many catalysts and news to release before the end of 2010 that should drive shareholder value:
- Rolling NDA filling for Marqibo in Adult ALL (that means a PDUFA date and the classic run-up period)
- Top-line Menadione Topical Lotion proof-of-concept data
- Initiate Phase 2 Menadione Topical Lotion trial
- Phase 2 Study of Marqibo in Patients With Metastatic Uveal Melanoma with an estimated primary completion date of December 2010 (Final data collection date for primary outcome measure)
2011 might also be a very good year for Hana Biosciences, with the potential approval of Marqibo in Adult ALL and the start of Phase III studies for other indications with Marqibo ($5B market).
For a reminder and due diligence on Hana Bioscience you may take a look at their corporate presentation:
http://files.shareholder.com/downloads/HNAB/1031314646x0x234717/40046CB8-6148-43F6-87AC-D3194C86932C/HNAB_081408.pdf
Recently Hana Biosciences has signed a deal with Warburg Pincus for up to $100M financing. Many investors have had a problem to digest this deal although it is a fantastic step for the development of Hana Biosciences. As soon as the dilution word comes out, investors are scared, but we are talking here about a financing from Warburg, investors must see them as a partner for the long term, let me explain who is Warburg Pincus and what they do.
Warburg Pincus takes a different approach to investing. Private equity at Warburg Pincus means investing at all stages of a company?s life-cycle: From founding start-ups and fostering growth in developing companies to leading complex recapitalizations or large-scale buy-outs of more mature businesses.
Years of private equity experience, deep industry knowledge, and unparalleled networks of resources and contacts help their investment professionals identify opportunities, attract leading entrepreneurs and management teams, and ultimately grow businesses in today?s rapidly changing environment.
They definitely know how to move a company from something small to something much larger.
The firm?s unique, globally-integrated partnership ensures that all of their resources are committed to the success of each portfolio company. Regardless of an investment?s stage of development, industry focus or geography ? the right people, with the right experience, are available to every entrepreneur and management team.
So why Hana Biosciences is so undervalued now?
Rather than understanding the long potential, many investors have seen this financial agreement for something bad in the short term. How many small biotechs today would have loved this $100M of available funding? The answer,a lot!
The recent R/S has scared Hana?s investors but that was something necessary. If you look at the Warburg Pincus portfolio they have many public companies that actually trade on the Nasdaq. With some good news to come before the end of this year you can bet that Hana will trade back to the Nasdaq soon.
Warburg is now deeply implicated with Hana Biosciences, they own the majority and you can bet that they have an exit strategy that will benefit to everybody because their business is to make money and to unlock the potential of companies.
Many investors are now afraid to invest in Hana Biosciences because of the potential dilution, but you can be sure that Warburg is not here to dump shares after the first higher trend, if you look at their portfolio they are invested in companies for many years, for some as early as 2000. Their goal is to stay long and maximize their profit. Warburg manages over $30 billion in assets, they don?t need to sell Hana?s shares as soon as the convet price is reached, they will rather take Hana to the next level and maximize their investment. They may also keep their shares until a potential buy out.
Let me remind you that with the reverse split, the convert prices for the Warburg?s shares did increase as well and are now $0.74 for the first preferred serie A1 shares and $1.10 for the serie A2.
We believe Warburg will follow Hana Biosciences for 3 to 5 years or even more, go through the approval of Marqibo in adult Ph-ALL, go through the Phase III study for the Front-line Agressive NHL (market potential of around $5B) at this point we might see Hana with a $500M to $800M market cap which is the average market cap of the companies that Warburg is invested in!
?We are very pleased to be able to provide the financing necessary to advance Hana?s promising product pipeline,? said Jonathan Leff, a Managing Director of Warburg Pincus. ?We look forward to working closely with the company?s board and management team to address important unmet needs in oncology.?
Healthcare Portfolio of Warburg Pincus (public companies only):
http://www.warburgpincus.com/portfolio/PortfolioByIndustry.aspx
Headquartered in South San Francisco, California, Hana Biosciences, Inc. (OTCBB: HNAB) is a publicly traded biopharmaceutical company focused on developing and commercializing novel treatments in oncology. Its lead drug, Marqibo, is a novel formulation of the widely used cancer drug Vincristine. Hana has completed a pivotal clinical trial with Marqibo in adults with Acute Lymphoblastic Leukemia (?ALL?), and the Company plans to file for Food and Drug Administration (?FDA?) approval in this indication. One of Hana?s other key development programs, Menadione, is completing Phase I studies for treatment of the serious skin toxicity caused by a major class of approved cancer drugs.
Market cap: $10M (with 20M shares)
Inspire Pharmaceuticals, Inc. (NASDAQ:ISPH) based in Raleigh, NC, is a biopharmaceutical company focused on developing and commercializing new treatments for diseases in the ophthalmic and respiratory areas. Founded in 1993 and publicly traded since 2000, Inspire currently markets three ophthalmology products and has two drugs in late-stage clinical development: Denufosol in Phase III for the treatment of Cystic Fibrosis and AzaSite for blepharitis.
Warburg Pincus led a private placement in Inspire in July 2007, and subsequently participated in a follow-on public offering in 2009. Since Warburg Pincus? original investment, Inspire has successfully completed one Phase III trial of Denufosol for the treatment of Cystic Fibrosis, launched AzaSite for the treatment of bacterial conjunctivitis, and announced positive Phase II trial results of AzaSite for the treatment of blepharitis. Additionally, in 2009, Warburg Pincus and the board recruited a new CEO in Adrian Adams, former President & CEO of Sepracor which he sold to Dainippon Sumitomo for $2.6 billion and former President & CEO of Kos which he sold to Abbott for $3.7 billion.
Market cap: $520M
Allos Therapeutics, Inc. (NASDAQ:ALTH) based in Westminster, Colorado, is a pharmaceutical company focused on developing and commercializing small molecule drugs for the treatment of cancer. The Company?s lead drug, Folotyn, was approved in September 2009 as the first FDA-approved drug for the treatment of relapsed or refractory peripheral T-cell lymphoma, a rare cancer whose sufferers have a very poor prognosis. Allos continues to advance several additional clinical studies of Folotyn in a wide range of other cancer types.
Warburg Pincus led a private placement in Allos in 2005 and subsequently participated in a follow-on public offering in 2008. In 2006, Warburg Pincus and the board recruited a new CEO in Paul Berns, former CEO of Bone Care International which he sold to Genzyme for $600 million. Under Paul?s leadership, Allos has successfully developed and launched Folotyn.
Market cap: $450M
ZymoGenetics, Inc. (NASDAQ:ZGEN) based in Seattle, WA, is a biopharmaceutical company focused on the development and commercialization of protein therapeutics. The Company launched its first drug on the US market in 2008, and has a strong pipeline of additional product candidates in development with meaningful commercial potential.
Warburg Pincus has been a significant investor in ZymoGenetics since 2000, when the firm led the spinout of Zymo from Novo Nordisk A/S, a major pharmaceutical company based in Denmark.
Market cap: $840M
Eurand (NASDAQ:EURX) headquartered in Milan, Italy, is a leading specialty pharmaceutical company that develops, manufactures and commercializes pharmaceutical and biopharmaceutical products. The Company operates from integrated research, development and production facilities in Italy, France and North America, and utilizes proprietary pharmaceutical technologies to develop novel products that have advantages over existing products or address unmet medical needs. Through collaboration arrangements with leading pharmaceutical companies, the Company has successfully applied its portfolio of existing and new technologies to drug products in a diverse range of therapeutic areas, including cardiovascular, gastrointestinal, pain, nutrition and respiratory. Eurand is currently developing and commercializing its own portfolio of therapeutic products to address conditions associated with cystic fibrosis and gastrointestinal disorders.
In partnership with management, Warburg Pincus acquired Eurand from American Home Products, Inc., now part of Pfizer, in 1999. Warburg Pincus subsequently invested additional funds into the Company, primarily to fund a number of acquisitions. Eurand completed its initial public offering on Nasdaq in May 2007 raising gross proceeds of $112 million.
Market cap: $520M
InterMune, Inc. (NASDAQ:ITMN) based in Brisbane, CA, is an independent biopharmaceutical company focused on developing and commercializing innovative therapies in pulmonology and hepatology. The Company was founded in 1999 with a strategy of acquiring clinical-stage products that could benefit from increased development and commercial focus within targeted therapeutic areas. The Company?s pulmonology pipeline includes pirfenidone for idiopathic pulmonary fibrosis (IPF), a progressive disease characterized by inflammation and scarring of the lungs. In hepatology, InterMune, together with its partner Roche, is developing a protease inhibitor, danoprevir (also known as RG7227 and ITMN-191), for the treatment of hepatitis C. InterMune also sells Actimmune, an interferon-gamma approved for the treatment of two rare congenital disorders.
Warburg Pincus led InterMune?s second round of private financing in 2000 to help fund product acquisitions and the execution of clinical trials for and commercialization of new product indications.
Market cap: $820M
WuXi (NYSE:WX) headquartered in Shanghai, China, is a premier contract research organization (CRO) with operations in China and the US. The Company was founded in 2000 as a provider of outsourced research chemistry lab services to the pharmaceutical industry, and has grown rapidly to become the global leader in this field. WuXi has expanded this core lab service business to include biology services, and has developed emerging capabilities in the related areas of clinical and commercial manufacturing and toxicology.
Warburg Pincus became a significant shareholder of WuXi beginning in 2008. Since Warburg Pincus? investment, WuXi has strengthened its management team, demonstrated strong operational performance despite macro-economic headwinds, and continued to expand its product offering into higher value-added services. In April 2010, WuXi announced a $1.6 billion merger with Charles River Labs to create the first global CRO offering fully integrated early-stage drug development services to clients worldwide.
Market cap: $1.17B
ev3 (NASDAQ: EVVV) headquartered in Plymouth, MN, is a leading global endovascular device company focused on the treatment of peripheral vascular and neurovascular disease. The company?s product portfolio includes a broad spectrum of over 100 products, including stents, embolic protection, PTA balloons and atherectomy devices for the peripheral vascular market, as well as embolic coils, liquid embolics, flow diversion, and access products for the neurovascular market.
Warburg Pincus founded ev3 in 2000, and has fostered the Company?s product development strategy by funding internal development programs and strategic acquisitions. Warburg Pincus also helped recruit a roster of highly talented managers with extensive experience in all aspects of the interventional devices business. ev3 completed an initial public offering in June 2005 and a follow-on public offering in April 2007. In October 2007, ev3 acquired FoxHollow Technologies, a developer of atherectomy devices for the treatment of peripheral vascular disease. In June 2009, ev3 acquired Chestnut Medical Technologies, a privately held company focused on developing neurovascular devices, including the Pipeline Embolization Device for aneurysms.
Market cap: June 1, 2010 ? Covidien plc (NYSE: COV) and ev3 Inc. (NASDAQ: EVVV) announced that they have signed a definitive merger agreement under which Covidien will acquire all of the outstanding shares of ev3 Inc. for $22.50 per share in cash, for a total of $2.6 billion, net of cash acquired.
Full Disclosure:
-Long position on HNAB
-The Clever bull has NOT been compensated in any way by Hana Biosciences or Warburg Pincus to promote or write this article.
The Clever Bull team.
By reading The Clever Bull you agree to the disclaimer, and thereby will not hold The Clever Bull accountable for any transactions or decisions you make. It is up to you to do your own due diligence.
I called Kristine for more information 2 days ago and no reply. I would think they would need a FDA approval of some kind to bring this to market or is this one of those test you send away for at $450 a pop and they send you back the results? I noticed they have a test for breast cancer too using the same type of product.